Author: Elsbernd, Paul M; Carter, Jonathan L
Title: Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review Cord-id: xstaqjno Document date: 2021_6_30
ID: xstaqjno
Snippet: Monoclonal antibody therapies have secured an important role in the therapeutic landscape for the treatment of both relapsing and progressive forms of multiple sclerosis due to their potent efficacy, convenient dosing schedules, and well-defined side effect profiles. Each therapy has unique risks and benefits associated with its specific mechanism of action which ultimately guides clinical decision-making for individual patients. This review will summarize the mechanisms of action, evidence lead
Document: Monoclonal antibody therapies have secured an important role in the therapeutic landscape for the treatment of both relapsing and progressive forms of multiple sclerosis due to their potent efficacy, convenient dosing schedules, and well-defined side effect profiles. Each therapy has unique risks and benefits associated with its specific mechanism of action which ultimately guides clinical decision-making for individual patients. This review will summarize the mechanisms of action, evidence leading to their approval, and clinically relevant considerations for each of the current monoclonal antibody therapies approved for the treatment of multiple sclerosis.
Search related documents:
Co phrase search for related documents- absolute reduction and lymphocyte count: 1, 2
- action different mechanism and adaptive innate: 1
- action different mechanism and mab monoclonal antibody: 1
- action mechanism and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- action mechanism and live vaccine: 1, 2
- action mechanism and long term safety: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date